“CRS is a big problem” Dr @MyMKaiser, Consultant Haemato-Oncologist The Institute of Cancer Research & Royal Marsden Hospital discusses Cytokine Release Syndrome (CRS) and its impact on cancer immunotherapy administration. Treatment is limited to specialist cancer clinics due to

Our Chief Executive Officer, Jeremy Skillington shares his thoughts on yesterday’s @OptimumComms Healthcare Conference. Jeremy was delighted to have been a part of the panel discussion on “Thriving in the tough times: scaling smart and staying strong”. Thank you to Optimum and

Our Chief Executive Officer Jeremy Skillington is joined by Luke O’Neill, Professor of Biochemistry at @tcddublin and Non-Executive Director & member of the Scientific Advisory Board at Poolbeg Pharma, in a @BusinessPlusMag interview. Jeremy and Luke share a 20+ year history

Reminder 💡Our Chief Executive Officer Jeremy Skillington will be participating in a panel discussion at the Optimum 17th Annual Healthcare Investor Conference on Thursday 9 October. 📍The King’s Fund, London ⌚14:15 🗣️ Panel: Thriving in the tough times: scaling smart and

Our recent news on the signed agreement with Accelerating Clinical Trials (ACT) to run the Phase 2a trial for POLB 001 was covered by @DDWJournal Drug Discovery World 🔹~30 patients across leading UK cancer centres 🔹Led by Dr Emma Searle at The Christie NHS Foundation Trust &

We were featured in a @Independent_ie article discussing Ireland’s potential to foster the growth of an indigenous pharmaceutical industry, highlighting the talent and ingredients available to make for a global success story. The article also highlights Poolbeg Pharma’s recent

We will be attending a retail investor lunch and invite you to join the discussion. 📅 7 October at 12:30pm 📍London City 🔵Attendees - CEO Jeremy Skillington, CFO Ian O'Connell & Exec Chair Cathal Friel Places are limited, register to attend by messaging @DavidBurton1971 to

Our CEO shares the highlights from our POLB 001 Trial update & Interim results: 🤝 Agreement signed with specialist blood cancer trial organisation – Accelerating Clinical Trials 💊Approved bispecific antibody drug secured for the trial at no cost to the Company 🏥Trial to

Catch up on Poolbeg's interim results with our CEO Jeremy Skillington, PhD & Proactive ✅ Approved bispecific antibody secured for the forthcoming POLB 001 Phase 2a trial at no cost to Poolbeg 💰£4.865m oversubscribed & upsized fundraise extends cash runway into 2027 🔬 ODD

Poolbeg Pharma has said it continues to believe it is well-positioned to deliver value for shareholders as it announced interim results for the six months to the end of the June

If you missed yesterday's Investor Meet Company featuring our Chief Executive Officer Jeremy Skillington, PhD & Principal Scientist Liam Tremble, then you can catch up on the link below: https://t.co/JPI7AmCypv #POLB #IMC #Investors

Our Chief Executive Officer Jeremy Skillington spoke with @VOXmarkets on our interim results for the six months to 30 June 2025. ✅ Approved bispecific antibody secured for the forthcoming POLB 001 Phase 2a trial at no cost to Poolbeg – trial in advanced stage of preparation

A reminder that we will be presenting with @InvestorMeetCo this evening at 5pm. Join Poolbeg’s CEO Jeremy Skillington and Principal Scientist Liam Tremble who will discuss the upcoming POLB 001 Phase 2a trial which will be conducted by ACT, having secured the supply of an

We have published our unaudited interim results: 💰 Cash balance of £10.0m (30 June 2025) including £4.865m gross proceeds raised as part of an oversubscribed & upsized fundraise ✅ Cash runway into 2027 supporting delivery of multiple key clinical milestones 🔬 POLB 001

If you missed yesterday’s announcement, you can catch up with @proactive_x and our CEO & Principal Scientist ✅ Approved bispecific antibody drug supply 🔬 Agreement signed with Accelerated Clinical Trials 👩‍🔬 Chief Investigator Dr Emma Searle, The Christie NHS Trust ➡️ POLB

Our Chief Executive Officer Jeremy Skillington and Principal Scientist Liam Tremble caught up with @VOXmarkets on this mornings update on the POLB 001 Phase 2a trial ✅ Approved bispecific antibody drug supply secured at no cost to Poolbeg 👉 Trial to be conducted by specialist

Following this morning’s announcement, we will be presenting with @InvestorMeetCo Join Poolbeg’s CEO Jeremy Skillington and Principal Scientist Liam Tremble who will discuss the upcoming POLB 001 Phase 2a trial which will be conducted by ACT, having secured the supply of an

We have signed an agreement for Accelerating Clinical Trials Limited (ACT) to conduct the upcoming POLB 001 Phase 2a trial & have secured supply of an approved bispecific antibody drug for the trial at no cost to the Company. 💡 POLB 001 has the potential to transform the

Our Principal Scientist, Liam Tremble, headed to this years’ International @Myeloma_Society’s 22nd Annual Meeting & Exposition in Toronto, Canada. Liam shares one of his top takeaways from a seminar with Emory and Mayo Clinic, where experts discussed the challenges and

Our @_investorsummit panel discussion was covered by @TMSreach 👉Building on today's immunotherapies ‼️The risk of CRS 🔬POLB 001 – a Preventative Therapy Targeting Cancer Immunotherapy-Induced CRS 🚀Market potential Read it here: https://t.co/BqRBOqlyZ2 #POLB #CRS

How much revenue could POLB 001 generate? 💰 “If the drug is successful, it could easily be several billion dollars” as said by panellist Brian White 🏥Cost of getting people out of hospital setting 🔬Treating current bottle neck which CRS creates 👉POLB 001 is a CRS